ERBB2 and non-small cell lung carcinoma: Additionally, we have highlighted the difficult trajectory of developing HER2 inhibitors, such as TKIs, antibodies, and ADCs, for patients with HER2-overexpressing or HER2-mutated NSCLC and compared it with the development of HER2-targeting treatment strategies for patients with metastatic breast cancer.